Patient characteristics
Age, y | |
| Median | 53 |
| Range | 1-72 |
| Sex, no. (%) | |
| Male | 116 (60) |
| Female | 77 (40) |
| Conditioning regimen, no. (%) | |
| TBI, 2 Gy | 48 (25) |
| Flu/TBI, 2 Gy | 142 (74) |
| None | 3 |
| Donors, no. (%) | |
| Related | 145 (75) |
| Unrelated | 48 (25) |
| Diseases, no. | |
| Hematologic malignancies | 168 |
| Multiple myeloma | 36 |
| MDS, MDS/AML | 28 |
| AML | 18 |
| NHL, low grade | 5 |
| NHL, intermediate/high grade | 22 |
| CLL | 19 |
| CML | 15 |
| HD | 14 |
| ALL | 8 |
| Waldenström macroglobulinemia | 3 |
| Renal cell carcinoma | 8 |
| Immunodeficiency disorders | 7 |
| Other | 10 |
| Disease risk*, no. | |
| Indolent | 81 |
| Aggressive | 102 |
Age, y | |
| Median | 53 |
| Range | 1-72 |
| Sex, no. (%) | |
| Male | 116 (60) |
| Female | 77 (40) |
| Conditioning regimen, no. (%) | |
| TBI, 2 Gy | 48 (25) |
| Flu/TBI, 2 Gy | 142 (74) |
| None | 3 |
| Donors, no. (%) | |
| Related | 145 (75) |
| Unrelated | 48 (25) |
| Diseases, no. | |
| Hematologic malignancies | 168 |
| Multiple myeloma | 36 |
| MDS, MDS/AML | 28 |
| AML | 18 |
| NHL, low grade | 5 |
| NHL, intermediate/high grade | 22 |
| CLL | 19 |
| CML | 15 |
| HD | 14 |
| ALL | 8 |
| Waldenström macroglobulinemia | 3 |
| Renal cell carcinoma | 8 |
| Immunodeficiency disorders | 7 |
| Other | 10 |
| Disease risk*, no. | |
| Indolent | 81 |
| Aggressive | 102 |
Flu indicates fludarabine; MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; HD, Hodgkin disease; and ALL, acute lymphocytic leukemia.
“Indolent” hematologic malignancies included CML in first complete remission (CR), AML in first CR, Philadelphia chromosome (Ph)—negative ALL in first CR, MDS refractory anemia (RA) with or without ringed sideroblasts (RS), myeloma in CR/partial remission (PR), aggressive NHL in first CR, HD in first CR, low-grade NHL and CLL.
“Aggressive” malignancies included renal cell carcinoma, other solid organ tumors, CML in accelerated phase (AP) or greater than CR1, AML beyond first CR, ALL beyond first CR, Ph-positive ALL in first CR, MDS other than RA (RS), multiple myeloma not in CR/PR, HD beyond first CR, and other NHL.
Disease risk only refers to malignant diseases.